Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Acurx Pharmaceuticals excels in Q1, eyes partnerships and funding

Acurx Pharmaceuticals showcased strong performance in Q1 2024 with positive data, successful FDA outcomes, and robust Phase III trial preparations.
While facing challenges in costs, timelines, and partnership negotiations, the company remains optimistic about its future prospects and strategic opportunities.
Strategic partnerships, regulatory advancements, and potential funding from the PASTEUR Act present avenues for growth and development in Acurx's antibiotic pipeline.
Overall, Acurx Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges effectively, and leverage opportunities for continued success.

Acurx Pharmaceuticals progresses ibezapolstat towards Phase III trials

Acurx Pharmaceuticals is advancing ibezapolstat towards Phase III trials for C. difficile infection treatment
Despite financial challenges, the company is actively seeking partnerships and funding opportunities
The successful Phase II meeting with the FDA and new patent grant are key milestones for Acurx
Optimism surrounds the potential impact of ibezapolstat on improving C. difficile treatment

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript

STATEN ISLAND, N.Y., Nov. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended September 30, 2021.

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

STATEN ISLAND, N.Y. , Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C.

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, at 8:30 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update

STATEN ISLAND, N.Y., Oct. 4, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster were presented on September 29 th at the Infectious Disease Society of America (IDSA) IDWeek™   2021 Virtual Conference entitled: "An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection.

Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek

Cidara Therapeutics

Iterum Therapeutics Plc

Melinta Therapeutics

Nabriva Therapeutics

Paratek Pharma

SCYNEXIS

Summit Therapeutics

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021.

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

STATEN ISLAND, N.Y., Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that management will participate in the A.G.P.

Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021

STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM  2021, taking place virtually from September 29 – October 3, 2021: Title: An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS™) Antibiotic, for Patients with Clostridioides difficile Infection Presenting Author: Professor Kevin Garey, PharmD, MS, University of Houston Date:  Wednesday, September 29, 2021 through Sunday, October 3, 2021 Poster Session: Enteric Infections Poster Number: 701 About Clostridioides difficile Infection (CDI).

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing a new class of antibiotics that could present the most meaningful changes to that sector in more than four decades. Its lead program utilizes ibezapolstat to target the debilitating C. difficile infection. Other pipeline programs and drugs are expected to target and treat numerous other gram-positive infections.That strategy could be advantageous on several fronts and...

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021.

Acurx Pharmaceuticals to Join the Russell Microcap Index®

STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P.

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Antibiotic resistant bacteria are increasing.

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

STATEN ISLAND, N.Y., Aug. 16, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended June 30, 2021.

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update

STATEN ISLAND, N.Y. , Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P.

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

STATEN ISLAND, N.Y., Aug. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Health Holland has awarded a grant of approximately $500,000 USD to Leiden University Medical Center (LUMC) and, through a three-party Consortium Agreement, Acurx Pharmaceuticals.

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

STATEN ISLAND, N.Y., July 28, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2021 second quarter financial results on Tuesday, August 17, 2021, at 8:30 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that it has filed a provisional patent application in the United States Patent and Trademark Office (USPTO).

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome

STATEN ISLAND, N.Y. , July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that using specimens from a Phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of CDI (Clostridioides difficile Infection) recurrence were associated with ibezapolstat compared to vancomycin.

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares of common stock, at a price to the public of $6.00 per share.

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

Elevation Oncology

GH Research PLC

Graphite Bio

Mister Car Wash

Alpha Teknova

Missfresh Ltd

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

7 Companies Go Public Today. What Investors Need to Know.

STATEN ISLAND, N.Y., June 25, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the pricing of an underwritten initial public offering of 2,500,000 newly-issued shares of its common stock at a price of $6.00 per share.

News for Acurx Pharmaceuticals LLC Stock (ACXP)